December 18, 2018
5:00 – 6:00 | Registration & Networking |
6:00 – 6:05 | Welcome and Opening RemarksBob Buderi, Xconomy |
6:05 – 6:15 | From Hope to Reality: The Expansion of Life Sciences in NYCMaria Gotsch, Partnership Fund for NYC |
6:15 – 6:45 | The Rgenix StoryThree brothers spun Rgenix out of Rockefeller University based on a technology meant to uncover cancer targets that others haven’t been able to find. It just raised a $40 million Series C and has a drug in human testing Masoud Tavozoie, Rgenix |
6:45 – 7:15 | The Quentis Therapeutics StoryFormed from the labs of former Weill Cornell Medicine dean Laurie Glimcher, Quentis is developing cancer drugs that counteract a method cells use to respond to stress. The startup is a product of Highline Therapeutics, a New York biotech incubator run by Versant Ventures Carlo Rizzuto, Quentis Therapeutics; Versant Ventures |
7:15 – 7:45 | The Flatiron Health StoryStarted by two young New York entrepreneurs, Nat Turner and Zach Weinberg, this developer of cancer-specific software was sold to Roche for $1.9 billion earlier this year. Bobby Green, Flatiron Health |
7:45 – 8:45 | Networking Reception |
Please note that this schedule is subject to change.